IDEAS home Printed from https://ideas.repec.org/a/bpj/fhecpo/v16y2013i2p47-56n4.html
   My bibliography  Save this article

Opportunities in the Economics of Personalized Health Care and Prevention

Author

Listed:
  • Meltzer David O.

Abstract

Personalized medicine is best viewed from a broad perspective of trying to use information about a patient to improve care. While “personalized medicine” often emphasizes the value of genetic information, traditional clinical approaches to personalizing care based on patient phenotype, provider and system-level factors should not be neglected. As these diverse approaches to personalization are examined, tools such as cost-effectiveness analysis can provide important insights into the value of these approaches, strategies for their implementation and dissemination, and priorities for future research. Such analyses are likely to be most insightful if they recognize that patient and provider behaviors are essential determinants of the value of treatments and that patient factors in particular may have large effects on the value of treatments and the need for interventions to improve decision making. These comments suggest three major areas of opportunity for economic analyses of personalized medicine: (1) traditional clinical approaches to personalized medicine, (2) multi-perspective studies of the benefits and costs of personalized medicine, and (3) the role of behavior in the value of personalized medicine.

Suggested Citation

  • Meltzer David O., 2013. "Opportunities in the Economics of Personalized Health Care and Prevention," Forum for Health Economics & Policy, De Gruyter, vol. 16(2), pages 13-22, June.
    • Handle: RePEc:bpj:fhecpo:v:16:y:2013:i:2:p:47-56:n:4
    DOI: 10.1515/fhep-2013-0012
    as

    Download full text from publisher

    File URL: https://doi.org/10.1515/fhep-2013-0012
    Download Restriction: For access to full text, subscription to the journal or payment for the individual article is required.
    File URL: https://libkey.io/10.1515/fhep-2013-0012?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. David O. Meltzer & Ties Hoomans & Jeanette W. Chung & Anirban Basu, 2011. "Minimal Modeling Approaches to Value of Information Analysis for Health Research," Medical Decision Making, , vol. 31(6), pages 1-22, November.
    2. David O. Meltzer & Ties Hoomans & Jeannette W. Chung & Anirban Basu & Kathryn J. Aikin & Amie C. O’Donoghue & John L. Swasy & Helen W. Sullivan & David G. T. Whitehurst & Stirling Bryan & Martyn Lew, 2011. "Minimal Modeling Approaches to Value of Information Analysis for Health Research," Medical Decision Making, , vol. 31(6), pages 785-786, November.
    3. Anirban Basu & David Meltzer, 2007. "Value of Information on Preference Heterogeneity and Individualized Care," Medical Decision Making, , vol. 27(2), pages 112-127, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Blythe Adamson & Dobromir Dimitrov & Beth Devine & Ruanne Barnabas, 2017. "The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 1(1), pages 1-12, March.
    2. Haitham Tuffaha & Claire Rothery & Natalia Kunst & Chris Jackson & Mark Strong & Stephen Birch, 2021. "A Review of Web-Based Tools for Value-of-Information Analysis," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 645-651, September.
    3. Anirban Basu & David Meltzer, 2012. "Private Manufacturers’ Thresholds to Invest in Comparative Effectiveness Trials," PharmacoEconomics, Springer, vol. 30(10), pages 859-868, October.
    4. Caroline S. Bennette & David L. Veenstra & Anirban Basu & Laurence H. Baker & Scott D. Ramsey & Josh J. Carlson, 2016. "Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group," Medical Decision Making, , vol. 36(5), pages 641-651, July.
    5. David Glynn & Vijay S. Gc & Karl Claxton & Chris Littlewood & Claire Rothery, 2024. "Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation," PharmacoEconomics, Springer, vol. 42(9), pages 919-928, September.
    6. Haitham Tuffaha, 2021. "Value of Information Analysis: Are We There Yet?," PharmacoEconomics - Open, Springer, vol. 5(2), pages 139-141, June.
    7. Manuel Antonio Espinoza & Andrea Manca & Karl Claxton & Mark Sculpher, 2018. "Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 28-40, February.
    8. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    9. Charles F. Manski, 2018. "Reasonable patient care under uncertainty," Health Economics, John Wiley & Sons, Ltd., vol. 27(10), pages 1397-1421, October.
    10. Dominic Hodgkin & Joanna Volpe‐Vartanian & Elizabeth L. Merrick & Constance M. Horgan & Andrew A. Nierenberg & Richard G. Frank & Sue Lee, 2012. "Customization in prescribing for bipolar disorder," Health Economics, John Wiley & Sons, Ltd., vol. 21(6), pages 653-668, June.
    11. Charles F. Manski, 2022. "Patient‐centered appraisal of race‐free clinical risk assessment," Health Economics, John Wiley & Sons, Ltd., vol. 31(10), pages 2109-2114, October.
    12. Anna Heath & Petros Pechlivanoglou, 2022. "Prioritizing Research in an Era of Personalized Medicine: The Potential Value of Unexplained Heterogeneity," Medical Decision Making, , vol. 42(5), pages 649-660, July.
    13. Charles F. Manski, 2023. "Using Limited Trial Evidence to Credibly Choose Treatment Dosage when Efficacy and Adverse Effects Weakly Increase with Dose," NBER Working Papers 31305, National Bureau of Economic Research, Inc.
    14. Rebecca Myerson & Darius Lakdawalla & Lisandro D. Colantonio & Monika Safford & David Meltzer, 2018. "Effects of expanding health screening on treatment – What should we expect? What can we learn?," Working Papers 2018-014, Human Capital and Economic Opportunity Working Group.
    15. Basu Anirban, 2013. "Personalized Medicine in the Context of Comparative Effectiveness Research," Forum for Health Economics & Policy, De Gruyter, vol. 16(2), pages 73-86, June.
    16. Basu, Anirban, 2011. "Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care," Journal of Health Economics, Elsevier, vol. 30(3), pages 549-559, May.
    17. Rebecca Mary Myerson & Darius Lakdawalla & Lisandro D. Colantonio & Monika Safford & David Meltzer, 2018. "Effects of Expanding Health Screening on Treatment - What Should We Expect? What Can We Learn?," NBER Working Papers 24347, National Bureau of Economic Research, Inc.
    18. Carl Bonander & Mikael Svensson, 2021. "Using causal forests to assess heterogeneity in cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 30(8), pages 1818-1832, August.
    19. David Glynn & John Giardina & Julia Hatamyar & Ankur Pandya & Marta Soares & Noemi Kreif, 2024. "Integrating decision modeling and machine learning to inform treatment stratification," Health Economics, John Wiley & Sons, Ltd., vol. 33(8), pages 1772-1792, August.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bpj:fhecpo:v:16:y:2013:i:2:p:47-56:n:4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Peter Golla (email available below). General contact details of provider: https://www.degruyter.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.